DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20181168

Evaluation of levetiracetam and valproic acid as monotherapy on quality of life in patients of generalized tonic clonic epilepsy

Sanjay K. Verma, Suman Bala, Yashpal Singh, Saurabh Kohli, Juhi Kalra, Dilip C. Dhasmana, Taruna Sharma

Abstract


Background: Quality of life plays an important role in patients of epilepsy and is the most neglected part during management. The antiepileptic drugs treatment results in seizure control but adversely affect the quality of life in patients.

Methods: An observational analytical study was conducted in the Department of pharmacology with Department of Neurology of Himalayan Institute of Medical Sciences, Dehradun over 12 months. 85 patients fulfilling the inclusion criteria with diagnosis of generalized tonic clonic seizures (GTCS) were enrolled and divided into two groups based on physicians discretion and followed up for 12 weeks. Patients were evaluated for quality of life by QOLIE-10 self administered questionnaire at 0 and 12 weeks, assessed for seizure control and drug related adverse effects.

Results: 85 patients were enrolled and divided into two treatment arms as per physician discretion, levetiracetam (41) and valproic acid group (44). Study drugs showed significant improvement in quality of life, levetiracetam showed mean change that was significantly greater than valproic acid (p=0.003) at 12 weeks. Patients who failed to achieve seizure control at 6 weeks were 17% patients in levetiracetam and 20% in valproic acid group, reason being non-adherence which was 17% and 20% respectively. Adverse events recorded with Levetiracetam (10), most common being increased sleep and with valproic acid (18), with most common being increased sleep and weight gain.

Conclusions: Levetiracetam treatment resulted in better quality of life, with similar seizure control but decreased number of adverse effect then Valproic acid.


Keywords


Generalized tonic clonic seizure, Levetiracetam, Quality of life in epilepsy, QOLIE-10, Valproic acid

Full Text:

PDF

References


Tatum WO IV, Benbadis S, Vale FL. The neurosurgical treatment of epilepsy. Arch Fam Med. 2000;9:1142-6.

Banerjee TK, Ray BK, Das SK, Hazra A, Ghosal MK, Chaudhuri A, et al. A longitudinal study of epilepsy in Kolkata, India. Epilepsia. 2010;51:2384-91.

Nelson LP, Savelli-Castillo I. New antiepileptic agents. Pediatr Dent. 2004;26:58-62.

Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav. 2003;4:659-66.

Viteri C, Codina M, Cobaleda S, Lahuerta J, Barriga J, Morales MD. Quality of life in Spanish epilepsy patients on monotherapy with Lamotrigine or Valproic acid. Seizure. 2010;19:432-38.

Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996;37(6):577-82.

Norsa’adah B, Zainab J, Knight A. The quality of life of people with epilepsy at a tertiary referral centre in Malaysia. Health and Quality of life Outcomes. 2013;11:143-48.

Shanmukhi S, Sita Jayalakshmi S, Anand B. Factors associated with quality of life in adult epilepsy patients-a hospital based study from south India. Res Neurol Int. 2015;1-5.

Jacoby A. Epilepsy and the quality of everyday life: findings from a study of people with well-controlled epilepsy. Soc Sci Med. 1992;34:657-66.

Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996;37(6):577-82.

Suresh S, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and safety of levetiracetam and carbamazepine as monotherapy in partial seizures. epilepsy research and treatment. 2015:1-6.

Marson A, Al-Kharusi A, Alwaidh M, Appleton R, Baker G, Chadwick D, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016-26.

Tatum WO IV, Benbadis S, Vale FL. The neurosurgical treatment of epilepsy. Arch Fam Med. 2000;9:1142-6.

Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Curr. 2011;11:9-11.

Ahmad N, Othaman NI, Islahudin F. Medication adherence and quality of life in epilepsy patients. Int J Pharm Pharm Sci. 2013;5(2):401-4.

Das K, Bannerjee M, Mondal GP, Devi LG, Singh OP, Mukherjee BB. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in urban epilepsy clinic. Seizure. 2007;16(7):601-07.